vorinostat has been researched along with DIPG Brain Tumors in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children's Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials." | 9.51 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. ( Adamson, PC; Adekunle, A; Blaney, SM; Buxton, A; Fouladi, M; Fox, E; Gajjar, A; Kilburn, LB; Krailo, M; Mansur, DB; Su, JM; Weigel, B, 2022) |
| "A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children's Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials." | 5.51 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. ( Adamson, PC; Adekunle, A; Blaney, SM; Buxton, A; Fouladi, M; Fox, E; Gajjar, A; Kilburn, LB; Krailo, M; Mansur, DB; Su, JM; Weigel, B, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Su, JM | 1 |
| Kilburn, LB | 1 |
| Mansur, DB | 1 |
| Krailo, M | 1 |
| Buxton, A | 1 |
| Adekunle, A | 1 |
| Gajjar, A | 1 |
| Adamson, PC | 1 |
| Weigel, B | 1 |
| Fox, E | 1 |
| Blaney, SM | 1 |
| Fouladi, M | 1 |
1 trial available for vorinostat and DIPG Brain Tumors
| Article | Year |
|---|---|
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report.
Topics: Astrocytoma; Brain Stem Neoplasms; Child; Diffuse Intrinsic Pontine Glioma; Histone Deacetylase Inhi | 2022 |